phrykt

Korro Bio, Inc. (KRRO): who owns it and who trades it

As of Nov 16, 2026, KRRO insiders reported 39 open-market sales worth $6.7M and 8 purchases worth $3.3M in the last 12 months, with 92% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jean Francois Formela (Director), with $6.1M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Korro Bio

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KRRO

107 funds and institutions reported KRRO shares worth $199M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Lynx1 Capital Management LP with 10.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Lynx1 Capital Management LP10.7%
Nantahala Capital Management, LLC9.2%
NEA Management Company, LLC9.0%
Venrock Adviser, LLC7.0%
Atlas Venture Life Science Advisors, LLC6.7%
Balyasny Asset Management L.P.6.6%
BlackRock, Inc.5.7%
Affinity Asset Advisors, LLC4.9%
Adage Capital Partners Gp, L.l.c.3.8%
ADAR1 Capital Management, LLC3.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Lynx1 Capital Management LP1.54M10.67%$20.3MNo change
Nantahala Capital Management, LLC1.32M9.15%$17.4M+100%
NEA Management Company, LLC1.30M9.00%$17.1MNo change
Venrock Adviser, LLC1.01M7.00%$13.3MNo change
Atlas Venture Life Science Advisors, LLC962,8846.68%$12.7M-15%
Balyasny Asset Management L.P.951,7836.60%$12.5M-8%
BlackRock, Inc.817,6215.67%$10.8M+78%
Affinity Asset Advisors, LLC706,9044.90%$9.3MNo change
Adage Capital Partners Gp, L.l.c.540,9683.75%$7.1M+137%
ADAR1 Capital Management, LLC540,0543.74%$7.1MNo change
Vanguard Capital Management LLC454,7783.15%$6M+46%
Driehaus Capital Management LLC450,0453.12%$5.9MNo change
TCG Crossover Management, LLC416,3012.89%$5.5MNo change
Kalehua Capital Management LLC405,0402.81%$5.3M+270%
Siren, L.L.C.347,7182.41%$4.6MNo change
AQR Capital Management LLC298,9742.07%$3.9M+12%
Geode Capital Management, LLC296,8702.06%$3.9M+71%
72 Investment Holdings, LLC276,8311.92%$3.6MNo change
State Street Corp232,5871.61%$3.1M+66%
Vanguard Portfolio Management LLC223,5511.55%$2.9M+50%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KRRO insiders reported $3.3M of open-market purchases and $6.7M of sales. 92% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$3.3M
8 trades, 3 people
Sales, 12 months
$6.7M
39 trades, 6 people
Sales under a 10b5-1 plan
92%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 13, 2026

Purchases and sales by month

$2.6M$2.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Jean Francois FormelaDirectorSale plan33,175$14.30$474KForm 4
Nov 12, 2026Jean Francois FormelaDirectorSale plan6,870$14.30$98.2KForm 4
Nov 11, 2026Jean Francois FormelaDirectorSale plan19,042$15.00$286KForm 4
Nov 11, 2026Jean Francois FormelaDirectorSale plan2,984$15.60$46.6KForm 4
Nov 11, 2026Jean Francois FormelaDirectorSale plan3,944$15.00$59.2KForm 4
Nov 11, 2026Jean Francois FormelaDirectorSale plan617$15.60$9.6KForm 4
Oct 26, 2026Lynx1 Capital Management LP +110% ownerPurchase25,124$11.75$295KForm 4
Oct 23, 2026Lynx1 Capital Management LP +110% ownerPurchase2,510$12.11$30.4KForm 4
Oct 22, 2026Lynx1 Capital Management LP +110% ownerPurchase12,175$9.68$118KForm 4
Oct 22, 2026Lynx1 Capital Management LP +110% ownerPurchase40,000$11.04$441KForm 4
Sep 14, 2026Jean Francois FormelaDirectorSale plan31,888$14.12$450KForm 4
Sep 14, 2026Jean Francois FormelaDirectorSale plan6,602$14.12$93.2KForm 4
Sep 11, 2026Jean Francois FormelaDirectorSale plan1,750$13.99$24.5KForm 4
Sep 11, 2026Jean Francois FormelaDirectorSale plan8,450$13.99$118KForm 4
Sep 11, 2026Oliver DolanVice presidentSale5$13.72$69Form 4
Sep 9, 2026Oliver DolanVice presidentSale6$13.60$82Form 4
Sep 8, 2026Oliver DolanVice presidentSale7,347$13.51$99.3KForm 4
Aug 26, 2026Jean Francois FormelaDirectorSale plan249$13.96$3.5KForm 4
Aug 26, 2026Jean Francois FormelaDirectorSale plan51$13.96$712Form 4
Aug 19, 2026Jean Francois FormelaDirectorSale plan23,584$14.00$330KForm 4
Aug 19, 2026Jean Francois FormelaDirectorSale plan4,884$14.00$68.4KForm 4
Aug 11, 2026Jean Francois FormelaDirectorSale plan1,775$13.96$24.8KForm 4
Aug 11, 2026Jean Francois FormelaDirectorSale plan368$13.96$5.1KForm 4
Aug 10, 2026Lynx1 Capital Management LP +110% ownerPurchase1,462$13.19$19.3KForm 4
Aug 6, 2026Lynx1 Capital Management LP +110% ownerPurchase5,222$11.40$59.5KForm 4
Aug 4, 2026Ram AiyarCEOSale5,802$10.84$62.9KForm 4
Jul 6, 2026Jean Francois FormelaDirectorSale plan817$13.96$11.4KForm 4
Jul 6, 2026Jean Francois FormelaDirectorSale plan8,506$13.96$119KForm 4
Jul 2, 2026Jean Francois FormelaDirectorSale plan85,955$14.03$1.2MForm 4
Jul 2, 2026Jean Francois FormelaDirectorSale plan14,745$14.03$207KForm 4
Jun 24, 2026Jean Francois FormelaDirectorSale plan40,679$14.60$594KForm 4
Jun 24, 2026Jean Francois FormelaDirectorSale plan114$14.98$1.7KForm 4
Jun 24, 2026Jean Francois FormelaDirectorSale plan666$14.98$10KForm 4
Jun 24, 2026Jean Francois FormelaDirectorSale plan6,979$14.60$102KForm 4
Jun 23, 2026Jean Francois FormelaDirectorSale plan101,579$14.25$1.4MForm 4
Jun 23, 2026Jean Francois FormelaDirectorSale plan17,426$14.25$248KForm 4
Jun 22, 2026Jean Francois FormelaDirectorSale plan3,382$13.95$47.2KForm 4
Jun 22, 2026Jean Francois FormelaDirectorSale plan580$13.95$8.1KForm 4
Jun 16, 2026Todd ChappellChief Operating OfficerSale3,168$10.83$34.3KForm 4
Jun 16, 2026Loic A VincentChief Scientific OfficerSale3,418$10.83$37KForm 4
Jun 16, 2026Jeffrey CerioGeneral CounselSale6,609$10.83$71.6KForm 4
Jun 16, 2026Oliver DolanVice presidentSale3,383$10.83$36.6KForm 4
May 29, 2026Ram AiyarCEOSale15,152$12.98$197KForm 4
May 28, 2026Jean Francois FormelaDirectorSale plan2,441$13.95$34.1KForm 4
May 28, 2026Jean Francois FormelaDirectorSale plan419$13.95$5.8KForm 4
Mar 31, 2026Weston Nichols +110% ownerPurchase520$10.60$5.5KForm 4
Mar 10, 2026Rick Yang10% ownerPurchase207,100$11.11$2.3MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jean Francois FormelaDirector–$6.1MNov 12, 2026
Rick Yang10% owner$2.3M–Mar 10, 2026
Lynx1 Capital Management LP10% owner$964K–Oct 26, 2026
Ram AiyarPresident and CEO, Director–$260KAug 4, 2026
Oliver DolanSenior Vice President, Finance–$136KSep 11, 2026
Jeffrey CerioGeneral Counsel–$71.6KJun 16, 2026
Loic A VincentChief Scientific Officer–$37KJun 16, 2026
Todd ChappellChief Operating Officer–$34.3KJun 16, 2026
Weston Nichols10% owner$5.5K–Mar 31, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KRRO short interest

High short interest. 11.9% of KRRO shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 46%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.75M KRRO shares were sold short, 11.9% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 213,901 shares, buying them all back would take about 8.2 trading days (days to cover).

Shares short, % of all shares

11.9%May 15Oct 3012.4%

Days to cover

8.2May 15Oct 3023.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.75M11.88%+1%213,9018.2
Oct 15, 20261.73M11.77%+3%179,9869.6
Sep 30, 20261.68M11.38%+8%255,6286.5
Sep 15, 20261.55M10.54%+5%130,31211.9
Aug 31, 20261.48M10.08%-2%71,16520.9
Aug 14, 20261.51M10.27%+5%105,84314.3
Jul 31, 20261.44M9.97%-1%157,0169.2
Jul 15, 20261.46M10.12%-14%229,5226.4
Jun 30, 20261.71M11.82%+29%367,1774.6
Jun 15, 20261.32M9.15%+4%144,4479.1
May 29, 20261.27M8.77%+6%166,4587.6
May 15, 20261.19M8.28%+7%104,31211.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Korro Bio company events

Korro Bio filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AgreementEnded an important agreement. Filing
  2. Oct 22, 2026AnnouncementKorro Bio, Inc. issued a press release announcing preclinical results for KRRO-111, its development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency. Filing
  3. Oct 5, 2026AnnouncementKorro Bio, Inc. issued a press release announcing that it has dosed the first cohort of participants in ANCHOR, its Phase 1/2 clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with urea cycle… Filing
  4. Aug 19, 2026AnnouncementKorro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with… Filing
  5. Aug 6, 2026AgreementKorro Bio, Inc., or Korro, entered into an exchange agreement with entities affiliated with Venrock Healthcare Capital Partners, together VenRock, pursuant to which (i) VenRock agreed to surrender an aggregate of 1,000,000 shares of Korro’s common stock, par value $0.001 per share, for no… Filing
  6. Jun 11, 2026VoteReported shareholder vote results. Filing
  7. May 19, 2026AnnouncementKorro Bio, Inc. issued a press release announcing the addition of KRRO-111 for the potential treatment of Alpha-1 Antitrypsin Deficiency to its pipeline of therapeutic programs in development. Filing
  8. May 7, 2026ResultsReleased financial results. Filing
  9. Mar 12, 2026ResultsReleased financial results. Filing
  10. Mar 9, 2026AgreementKorro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement pursuant to the exemption in Section 4(a)(2) of the Securities Act of 1933, as amended, or the 1933 Act: (i) an… Filing
  11. Jan 27, 2026AnnouncementKorro Bio, Inc. hosted a virtual Analyst Day. Filing
  12. Jan 15, 2026AnnouncementKorro Bio, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. Filing
  13. Dec 18, 2025LeadershipKorro Bio, Inc., or Korro, entered into an amended and restated employment agreement with Jeffrey Cerio, which amended and restated his employment agreement dated August 28, 2024. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Korro Bio financials

Famous investors that hold KRRO

2 of the 50 well-known investors we track reported holding KRRO in their latest 13F filing. The largest position is Jim Simons's, worth $651K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202665,662$651K0.0%-41%
Israel Englander · Millennium ManagementQ3 202660,000$595K0.0%-49%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named KRRO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A5.9%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A5.9%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A9.9%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A9.9%
Nov 12, 2026Adage Capital Management, L.P.13G6.8%
Nov 12, 2026Adage Capital Management, L.P.13G6.8%
Oct 27, 2026BlackRock, Inc.13G/A4.9%
Oct 27, 2026BlackRock, Inc.13G/A4.9%

Questions about Korro Bio, Inc. (KRRO) stock

Who owns the most KRRO stock?

The largest reported owner of Korro Bio, Inc. (KRRO) is Lynx1 Capital Management LP, with 10.7% of the company. In total, 107 funds and institutions reported holding KRRO at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are KRRO insiders buying or selling?

In the last 12 months, KRRO insiders reported 8 open-market purchases worth $3.3M and 39 sales worth $6.7M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in KRRO?

As of Oct 30, 2026, 1.75M KRRO shares were sold short, 11.9% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 213,901 shares, buying them all back would take about 8.2 trading days (days to cover). See the history.

Which famous investors hold KRRO?

2 of the 50 well-known investors we track reported KRRO in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $651K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.